Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NQM4
UPID:
DAAF6_HUMAN
Alternative names:
PIH1 domain-containing protein 3; Sarcoma antigen NY-SAR-97
Alternative UPACC:
Q9NQM4; D3DUX5; Q86WE1
Background:
Dynein axonemal assembly factor 6, also known as PIH1 domain-containing protein 3 and Sarcoma antigen NY-SAR-97, plays a crucial role in the cytoplasmic pre-assembly of axonemal dynein. This protein is pivotal for the proper function and structure of motile cilia, which are essential for fluid movement across cell surfaces.
Therapeutic significance:
Given its involvement in primary ciliary dyskinesia, particularly Ciliary dyskinesia, primary, 36, X-linked, understanding the role of Dynein axonemal assembly factor 6 could open doors to potential therapeutic strategies. This condition leads to severe respiratory infections and can result in situs inversus in some patients, highlighting the protein's significance in disease.